Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 166

1.

NSC-631570 (Ukrain) in the palliative treatment of pancreatic cancer. Results of a phase II trial.

Gansauge F, Ramadani M, Pressmar J, Gansauge S, Muehling B, Stecker K, Cammerer G, Leder G, Beger HG.

Langenbecks Arch Surg. 2002 Mar;386(8):570-4. Epub 2002 Feb 13.

PMID:
11914932
[PubMed - indexed for MEDLINE]
2.

The clinical efficacy of adjuvant systemic chemotherapy with gemcitabine and NSC-631570 in advanced pancreatic cancer.

Gansauge F, Ramadani M, Schwarz M, Beger HG, Lotspeich E, Poch B.

Hepatogastroenterology. 2007 Apr-May;54(75):917-20.

PMID:
17591092
[PubMed - indexed for MEDLINE]
3.

Randomized phase III trial of gemcitabine plus cisplatin compared with gemcitabine alone in advanced pancreatic cancer.

Heinemann V, Quietzsch D, Gieseler F, Gonnermann M, Schönekäs H, Rost A, Neuhaus H, Haag C, Clemens M, Heinrich B, Vehling-Kaiser U, Fuchs M, Fleckenstein D, Gesierich W, Uthgenannt D, Einsele H, Holstege A, Hinke A, Schalhorn A, Wilkowski R.

J Clin Oncol. 2006 Aug 20;24(24):3946-52.

PMID:
16921047
[PubMed - indexed for MEDLINE]
4.

Randomized phase III study of exatecan and gemcitabine compared with gemcitabine alone in untreated advanced pancreatic cancer.

Abou-Alfa GK, Letourneau R, Harker G, Modiano M, Hurwitz H, Tchekmedyian NS, Feit K, Ackerman J, De Jager RL, Eckhardt SG, O'Reilly EM.

J Clin Oncol. 2006 Sep 20;24(27):4441-7.

PMID:
16983112
[PubMed - indexed for MEDLINE]
5.

Gemcitabine alone or with cisplatin for the treatment of patients with locally advanced and/or metastatic pancreatic carcinoma: a prospective, randomized phase III study of the Gruppo Oncologia dell'Italia Meridionale.

Colucci G, Giuliani F, Gebbia V, Biglietto M, Rabitti P, Uomo G, Cigolari S, Testa A, Maiello E, Lopez M.

Cancer. 2002 Feb 15;94(4):902-10.

PMID:
11920457
[PubMed - indexed for MEDLINE]
Free Article
6.

Irinotecan plus raltitrexed vs raltitrexed alone in patients with gemcitabine-pretreated advanced pancreatic adenocarcinoma.

Ulrich-Pur H, Raderer M, Verena Kornek G, Schüll B, Schmid K, Haider K, Kwasny W, Depisch D, Schneeweiss B, Lang F, Scheithauer W.

Br J Cancer. 2003 Apr 22;88(8):1180-4.

PMID:
12698181
[PubMed - indexed for MEDLINE]
Free PMC Article
7.

A double-blind placebo-controlled, randomised study comparing gemcitabine and marimastat with gemcitabine and placebo as first line therapy in patients with advanced pancreatic cancer.

Bramhall SR, Schulz J, Nemunaitis J, Brown PD, Baillet M, Buckels JA.

Br J Cancer. 2002 Jul 15;87(2):161-7.

PMID:
12107836
[PubMed - indexed for MEDLINE]
Free PMC Article
8.

Randomised trial of gemcitabine versus flec regimen given intra-arterially for patients with unresectable pancreatic cancer.

Cantore M, Fiorentini G, Luppi G, Rosati G, Caudana R, Piazza E, Comella G, Ceravolo C, Miserocchi L, Mambrini A, Del Freo A, Zamagni D, Aitini E, Marangolo M.

J Exp Clin Cancer Res. 2003 Dec;22(4 Suppl):51-7.

PMID:
16767907
[PubMed - indexed for MEDLINE]
9.

BAYPAN study: a double-blind phase III randomized trial comparing gemcitabine plus sorafenib and gemcitabine plus placebo in patients with advanced pancreatic cancer.

Gonçalves A, Gilabert M, François E, Dahan L, Perrier H, Lamy R, Re D, Largillier R, Gasmi M, Tchiknavorian X, Esterni B, Genre D, Moureau-Zabotto L, Giovannini M, Seitz JF, Delpero JR, Turrini O, Viens P, Raoul JL.

Ann Oncol. 2012 Nov;23(11):2799-805. doi: 10.1093/annonc/mds135. Epub 2012 Jul 5.

PMID:
22771827
[PubMed - indexed for MEDLINE]
Free Article
10.

Randomized phase II comparison of dose-intense gemcitabine: thirty-minute infusion and fixed dose rate infusion in patients with pancreatic adenocarcinoma.

Tempero M, Plunkett W, Ruiz Van Haperen V, Hainsworth J, Hochster H, Lenzi R, Abbruzzese J.

J Clin Oncol. 2003 Sep 15;21(18):3402-8. Epub 2003 Jul 28.

PMID:
12885837
[PubMed - indexed for MEDLINE]
11.

Gemcitabine versus FLEC regimen given intra-arterially to patients with unresectable pancreatic cancer: a prospective, randomized phase III trial of the Italian Society for Integrated Locoregional Therapy in Oncology.

Cantore M, Fiorentini G, Luppi G, Rosati G, Caudana R, Piazza E, Comella G, Ceravolo C, Miserocchi L, Mambrini A, Del Freo A, Zamagni D, Rabbi C, Marangolo M.

J Chemother. 2004 Dec;16(6):589-94.

PMID:
15700852
[PubMed - indexed for MEDLINE]
12.

Gemcitabine or gemcitabine plus cisplatin for in 42 patients with locally advanced or metastatic pancreatic cancer.

Wang X, Ni Q, Jin M, Li Z, Wu Y, Zhao Y, Feng F.

Zhonghua Zhong Liu Za Zhi. 2002 Jul;24(4):404-7.

PMID:
12408777
[PubMed - indexed for MEDLINE]
13.

A multicenter phase III trial comparing irinotecan-gemcitabine (IG) with gemcitabine (G) monotherapy as first-line treatment in patients with locally advanced or metastatic pancreatic cancer.

Stathopoulos GP, Syrigos K, Aravantinos G, Polyzos A, Papakotoulas P, Fountzilas G, Potamianou A, Ziras N, Boukovinas J, Varthalitis J, Androulakis N, Kotsakis A, Samonis G, Georgoulias V.

Br J Cancer. 2006 Sep 4;95(5):587-92. Epub 2006 Aug 8.

PMID:
16909140
[PubMed - indexed for MEDLINE]
Free PMC Article
14.

Biweekly high-dose gemcitabine alone or in combination with capecitabine in patients with metastatic pancreatic adenocarcinoma: a randomized phase II trial.

Scheithauer W, Schüll B, Ulrich-Pur H, Schmid K, Raderer M, Haider K, Kwasny W, Depisch D, Schneeweiss B, Lang F, Kornek GV.

Ann Oncol. 2003 Jan;14(1):97-104.

PMID:
12488300
[PubMed - indexed for MEDLINE]
Free Article
15.

[Locally advanced unresectable pancreatic cancer: Induction chemoradiotherapy followed by maintenance gemcitabine versus gemcitabine alone: Definitive results of the 2000-2001 FFCD/SFRO phase III trial].

Barhoumi M, Mornex F, Bonnetain F, Rougier P, Mariette C, Bouché O, Bosset JF, Aparicio T, Mineur L, Azzedine A, Hammel P, Butel J, Stremsdoerfer N, Maingon P, Bedenne L, Chauffert B.

Cancer Radiother. 2011 Jun;15(3):182-91. doi: 10.1016/j.canrad.2010.10.001. Epub 2011 Feb 10. French.

PMID:
21315644
[PubMed - indexed for MEDLINE]
16.

A phase II randomized study of cetuximab and bevacizumab alone or in combination with gemcitabine as first-line therapy for metastatic pancreatic adenocarcinoma.

Ko AH, Youssoufian H, Gurtler J, Dicke K, Kayaleh O, Lenz HJ, Keaton M, Katz T, Ballal S, Rowinsky EK.

Invest New Drugs. 2012 Aug;30(4):1597-606. doi: 10.1007/s10637-011-9691-8. Epub 2011 Jun 1.

PMID:
21629990
[PubMed - indexed for MEDLINE]
17.

PS-341 and gemcitabine in patients with metastatic pancreatic adenocarcinoma: a North Central Cancer Treatment Group (NCCTG) randomized phase II study.

Alberts SR, Foster NR, Morton RF, Kugler J, Schaefer P, Wiesenfeld M, Fitch TR, Steen P, Kim GP, Gill S.

Ann Oncol. 2005 Oct;16(10):1654-61. Epub 2005 Aug 5.

PMID:
16085692
[PubMed - indexed for MEDLINE]
Free Article
18.

Comparison of gemcitabine versus the matrix metalloproteinase inhibitor BAY 12-9566 in patients with advanced or metastatic adenocarcinoma of the pancreas: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group.

Moore MJ, Hamm J, Dancey J, Eisenberg PD, Dagenais M, Fields A, Hagan K, Greenberg B, Colwell B, Zee B, Tu D, Ottaway J, Humphrey R, Seymour L; National Cancer Institute of Canada Clinical Trials Group.

J Clin Oncol. 2003 Sep 1;21(17):3296-302.

PMID:
12947065
[PubMed - indexed for MEDLINE]
19.

Randomized phase II study of gemcitabine administered at a fixed dose rate or in combination with cisplatin, docetaxel, or irinotecan in patients with metastatic pancreatic cancer: CALGB 89904.

Kulke MH, Tempero MA, Niedzwiecki D, Hollis DR, Kindler HL, Cusnir M, Enzinger PC, Gorsch SM, Goldberg RM, Mayer RJ.

J Clin Oncol. 2009 Nov 20;27(33):5506-12. doi: 10.1200/JCO.2009.22.1309. Epub 2009 Oct 26.

PMID:
19858396
[PubMed - indexed for MEDLINE]
Free PMC Article
20.

Randomized phase III trial of gemcitabine plus cisplatin compared with single-agent gemcitabine as first-line treatment of patients with advanced pancreatic cancer: the GIP-1 study.

Colucci G, Labianca R, Di Costanzo F, Gebbia V, Cartenì G, Massidda B, Dapretto E, Manzione L, Piazza E, Sannicolò M, Ciaparrone M, Cavanna L, Giuliani F, Maiello E, Testa A, Pederzoli P, Falconi M, Gallo C, Di Maio M, Perrone F; Gruppo Oncologico Italia Meridionale (GOIM); Gruppo Italiano per lo Studio dei Carcinomi dell'Apparato Digerente (GISCAD); Gruppo Oncologico Italiano di Ricerca Clinica (GOIRC).

J Clin Oncol. 2010 Apr 1;28(10):1645-51. doi: 10.1200/JCO.2009.25.4433. Epub 2010 Mar 1.

PMID:
20194854
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk